LSX World Congress 2023

Fish's Gwilym Attwell will moderate the panel "What I Wish I Had Known When Taking Assets to the U.S. Market" at LSX World Congress 2023 on Wednesday, May 3.

Fish is a proud sponsor of LSX World Congress, which aims to connect life science executives with the partners they need to flourish. The event brings together CEOs and senior decision makers from the world's most innovative biopharma, medtech, and healthtech companies with investors and industry leaders. Together, they share best practices and forge partnerships — all geared at putting capital and ideas to work to help create the world's future medicines and improve patient outcomes. From therapeutics to techbio, devices to digital health, deep tech to platform tech, and diagnostics to delivery tools, LSX World Congress represents the breadth, depth, and convergence of the cutting-edge research and technology driving advances in the healthcare industry.

What I Wish I Had Known When Taking Assets to the U.S. Market
Wednesday, May 3, 2023 | 2:50 p.m. BST

Entering new markets comes with many challenges: intellectual property licensing, transactions, agreements — the list goes on. Entering the U.S. market is becoming a strategic consideration ever earlier in the growth process for many biotech companies, and experience, knowledge, and effective due diligence in navigating the whole process can save time, money, and headaches down the line. A multi-stakeholder panel will discuss how companies and their investors can optimize their IP portfolios for entry to the U.S., ensure long-term success in securing capital from investors, prepare for licensing and transactions, and minimize litigation risk. Discussion topics will include the following:

How to put yourself in the best possible position for investment and deals

What assets investors and partners will want to see in your IP portfolio

How to protect privileged and confidential information during the due diligence process

Experience and lessons learned about "what I wish I had known" and "what I think I could have done better"


  • Gwilym Attwell, Principal, Fish & Richardson


  • Kieran Rooney, SVP, Head of BD, Amryt Pharma
  • Damien O'Farrell, Assistant General Counsel (Patents), GSK
  • Eliot Forster, CEO, F-star Therapeutics
  • Melya Hughes Crameri, Partner, Ventac Partners

To learn more, click here.